Naringin targets Zeb1 to suppress osteosarcoma cell proliferation and metastasis

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Naringin, a citrus bioflavonoid, possesses anti-inflammatory, cardio-, and neuroprotective properties.
• Naringin demonstrates antitumor activity across various cancer types, including osteosarcoma, a prevalent bone cancer.

Purpose of the Study:

• To investigate the therapeutic potential of naringin in human osteosarcoma.
• To elucidate the mechanism by which naringin affects osteosarcoma cell behavior, focusing on Zeb1.

Main Methods:

• In vitro studies using human osteosarcoma cells to assess proliferation, invasion, and apoptosis.
• Gene silencing (siRNA) and overexpression of Zeb1 to validate its role.
• In vivo studies in mice using osteosarcoma cell xenografts.

Main Results:

• Naringin inhibited osteosarcoma cell proliferation and invasion while inducing apoptosis.
• Naringin's effects were mediated by the inhibition of Zeb1 (zinc finger E-box binding homeobox 1).
• Naringin reduced tumor formation and Zeb1-related protein expression in vivo.

Conclusions:

• Naringin effectively suppresses osteosarcoma progression by downregulating Zeb1.
• Naringin demonstrates preclinical efficacy as a potential therapeutic agent for osteosarcoma treatment.